Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. [electronic resource]
Producer: 20120626Description: 834-45 p. digitalISSN:- 1097-0045
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- therapeutic use
- Biomarkers, Tumor -- blood
- Cancer Vaccines -- therapeutic use
- Cytokines -- blood
- Disease Progression
- Docetaxel
- Humans
- Immunity, Humoral
- Interleukin-6 -- blood
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Orchiectomy
- Precision Medicine
- Prospective Studies
- Prostatic Neoplasms -- drug therapy
- Taxoids -- therapeutic use
- Treatment Failure
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.